OMass Therapeutics strengthens its leadership team

Oxford, UK, 6 December 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey PhD to Senior Vice President, Discovery and Non-Clinical, effective immediately.

Hsin joined OMass in July 2018 and has been serving as SVP, Finance and Operations. Prior to joining OMass, she spent 16 years at GSK in a variety of leadership roles, including heading Finance, Strategy and Operations for GSK’s Rare Diseases Unit. Hsin completed her BA (Hons) in Biological Sciences and D.Phil. in Genetics and Immunology at the University of Oxford, and qualified as a Chartered Accountant at PwC. She currently serves on the Board of the Cell and Gene Therapy Catapult (CGT Catapult).

Jon joined OMass in July 2022 as VP, Head of Medicinal Chemistry. Jon has over 20 years of experience in drug discovery across a variety of therapeutic areas, including oncology, CNS and metabolic disorders and a range of therapeutic modalities. Jon joined OMass from Nanna Therapeutics, where he was Head of Chemistry, leading a portfolio of mitochondrial-targeted programmes to treat rare diseases. Prior to that, he was Director of Chemistry at Azeria Therapeutics, a company he helped spin out from the University of Cambridge. Previous roles include Senior Group Leader at Cancer Research Technology and Senior Scientist and Project Lead at Spirogen, where he established and led its antibody-drug conjugate programme. He started his medicinal chemistry career at Vernalis as a Senior Scientist working on a variety of GPCR targets. He has a PhD in Organic Chemistry obtained from the University of Loughborough.

Hsin Loke, Chief Operating Officer and Senior Vice President, Finance at OMass Therapeutics, said:

I am delighted to take on the role of COO at OMass, further supporting the Company’s strategic goals. Selecting a clinical candidate for our MC2 programme is a key milestone for our team and a testament to our focus and dedication. I look forward to helping drive more advancements in our pipeline of small molecule therapeutics targeting rare diseases and immunological conditions.

Jon Roffey, Senior Vice President, Discovery and Non-Clinical at OMass Therapeutics, added:

“Our OdyssION™ platform is revolutionising how we interrogate the fundamental interactions driving life, allowing us to develop differentiated small molecules against complex-bound and membrane targets. As SVP, Discovery and Non-Clinical, I am excited to continue using my drug discovery expertise to develop innovative treatments for rare immunological and genetic diseases with high unmet patient need.”